Cost-effectiveness analysis of voclosporin vs mycophenolate or belimumab in the treatment of patients with lupus nephritis from the Spanish National Healthcare System perspective (ERA 2025) - Apr 15, 2025 - Abstract #1672; Pres time: Jun 5, 2025; 09:45 AM - 11:15 AM; Location: Haydn; P3 | "This study aims to estimate the cost-effectiveness of VCS in combination with mycophenolate mofetil (MMF) vs MMF alone or vs belimumab (BEL) in combination with MMF or cyclophosphamide (CYC), for Spanish patients with LN III-V (and mixed classes) from the perspective of the Spanish National Health System (NHS). In the current situation, the use of VCS could provide more health benefits and cost-savings for the Spanish NHS. Even if BEL price was heavily reduced, VCS would still be a cost-effective intervention for treatment of patients with LN III-IV (and mixed classes)."
Clinical • Cost effectiveness • HEOR • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Nuria Paladio Duran1; Laura Salinas-Ortega2; Alberto de la Cuadra-Grande2; Itziar Oyagüez2
|